| Polymorphism of the gene - IL-28B | Price 16 500 tenge |
Interleukin 28B gene is responsible for resistance to viral infections and efficiency of chronic hepatitis C treatment with ribavirin (Rebetol) and PEG-interferon (PegIntron). Determination of gene polymorphism makes it possible to determine the prognosis of the course of infection, treatment efficacy, determine the timing of treatment and doses of drugs without causing unnecessary harm to the patient.
Biomaterial Venous blood with EDTA. No special preparation for the study is required.
Deadline 14 working days
Who is recommended ?
Patients before initiation of HCV therapy:
a) in predicting response to treatment
b) in choosing treatment tactics for chronic HCV
According to the literature, only in 40-50% of cases of hepatitis C virus genotype 1, antiviral therapy gives a positive result. In the case of other genotypes of the virus, this figure reaches 75% after only 6 months. Therefore, in the case of genotype 1 virus it is very important to give an accurate prognosis of success. In addition to known clinical indicators such as age, sex, body mass index, viral load, individual genetic factors are now being evaluated to predict the results of initial or repeated antiviral therapy.
According to recent studies, it is reasonable to examine sequences at the lambda interferon type III (IL28B) gene site on chromosome 19 to predict therapy outcomes. These variants, by which the success of therapy can be predicted more accurately than by clinical parameters, are investigated as part of the genetic test.
Results:
1. Recommended screening algorithm before starting hepatitis C therapy
2.Genetic polymorphisms associated with resistance to chronic hepatitis C treatment with interferon and ribavirin
Additional information:
Article "IL 28B gene polymorphism in antiviral therapy for chronic hepatitis C">>>
Article Special Issue of ALMATY GEPATOLOGY 2014 "Viral Hepatitis C in Kazakhstan" by Nersesov AV, Solomadin MV, Kaliaskarova KS, Kosherova BN, Raisova AM.